correction ada-scid stem cell gene therapy combined nonmyeloablative conditioning
hematopoietic stem cell hsc gene therapy adenosine deaminase ada-deficient severe combined immunodeficiency scid shown limited clinical efficacy small proportion engrafted genetically corrected hscs describe improved protocol gene transfer hscs associated nonmyeloablative conditioning protocol used two patients enzyme replacement therapy available allowed effect gene therapy alone evaluated sustained engraftment engineered hscs differentiation multiple lineages resulted increased lymphocyte counts improved immune functions including antigen-specific responses lower toxic metabolites patients currently home clinically well normal growth development results indicate safety efficacy hsc gene therapy combined nonmyeloablative conditioning treatment scid
